1M6MYTD1A5AMAX
Caricamento quotazioni...
Previsioni
| Acquista |
0 |
| Mantieni |
1 |
| Vendi |
0 |
Notizie Vai al feed delle notizie
Predictive Oncology approves increase to equity incentive plan and issuance of pre‑funded warrants
At the annual meeting, shareholders voted to increase the 2024 Equity Incentive Plan by 1,000,000 shares and to issue 14,903,393 common shares that will be issued upon exercise of pre‑funded warrants. The elections of directors Daniel E. Handley and Chuck Nuzum were confirmed and KPMG was appointed as independent auditors. Predictive Oncology also reported a significant net loss in Q3 2025, but said it has regained compliance with NASDAQ’s minimum stockholders’ equity requirement and is pursuing initiatives to enter the AI infrastructure market. » Altro su de.investing.com
Dati finanziari dell'azienda
| (EUR) | giu 2026 | |
|---|---|---|
| Ricavi | 2,82 Mln | 123.699,49% |
| Utile lordo | 176,69K | 1440,23% |
| Utile netto | -15,08 Mln | 758,24% |
| EBITDA | -3,52 Mln | 129,57% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 103,67 Mln € |
Numero di azioni | 11,49 Mln |
Massimo/minimo a 52 settimane | 27,71 € - 0,89 € |
| Dividendi | No |
Beta | 3,47 |
Rapporto P/E | -0,07 |
Rapporto PEG | 0,00 |
Rapporto P/B | 6,04 |
Rapporto P/S | 36,82 |
Profilo aziendale
| Nome | Predictive Oncology |
| CEO | Christopher Miglino |
| Dipendenti | 14 |
Scopri gli asset
Gli azionisti di Predictive Oncology investono anche nei seguenti asset
